tetano
Editor, Senior Moderator
Clin Infect Dis
. 2022 Dec 27;ciac966.
doi: 10.1093/cid/ciac966. Online ahead of print.
Three-month symptom profiles among symptomatic adults with positive and negative SARS-CoV-2 tests: a prospective cohort study from the INSPIRE group
Erica S Spatz[SUP] 1 [/SUP], Michael Gottlieb[SUP] 2 [/SUP], Lauren E Wisk[SUP] 3 [/SUP], Jill Anderson[SUP] 4 [/SUP], Anna Marie Chang[SUP] 5 [/SUP], Nicole L Gentile[SUP] 6 [/SUP], Mandy J Hill[SUP] 7 [/SUP], Ryan M Huebinger[SUP] 7 [/SUP], Ahamed H Idris[SUP] 8 [/SUP], Jeremiah Kinsman[SUP] 9 [/SUP], Katherine Koo[SUP] 10 [/SUP], Shu-Xia Li[SUP] 11 [/SUP], Samuel McDonald[SUP] 12 [/SUP], Ian D Plumb[SUP] 13 [/SUP], Robert Rodriguez[SUP] 14 [/SUP], Sharon Saydah[SUP] 13 [/SUP], Benjamin Slovis[SUP] 5 [/SUP], Kari A Stephens[SUP] 15 [/SUP], Elizabeth R Unger[SUP] 16 [/SUP], Ralph C Wang[SUP] 14 [/SUP], Huihui Yu[SUP] 11 [/SUP], Bala Hota[SUP] 17 [/SUP], Joann G Elmore[SUP] 3 [/SUP], Robert A Weinstein[SUP] 18 [/SUP], Arjun Venkatesh[SUP] 19 [/SUP]
Affiliations
Abstract
Background: Long-term symptoms following SARS-CoV-2 infection are a major concern, yet their prevalence is poorly understood.
Methods: We conducted a prospective cohort study comparing adults with SARS-CoV-2 infection (COVID+) with adults who tested negative (COVID-), enrolled within 28 days of an FDA-approved SARS-CoV2 test result for active symptoms. Sociodemographic characteristics, symptoms of SARS-CoV-2 infection (assessed with the CDC Person Under Investigation Symptom List), and symptoms of post-infectious syndromes (i.e., fatigue, sleep quality, muscle/joint pains, unrefreshing sleep, and dizziness/fainting, assessed with CDC Short Symptom Screener for myalgic encephalomyelitis/chronic fatigue syndrome) were assessed at baseline and 3 months via electronic surveys sent via text or email.
Results: Among the first 1,000 participants, 722 were COVID + and 278 were COVID-. Mean age was 41.5 (SD 15.2); 66.3% were female, 13.4% were Black, and 15.3% were Hispanic. At baseline, SARS-CoV-2 symptoms were more common in the COVID + group than the COVID - group. At 3-months, SARS-CoV-2 symptoms declined in both groups although were more prevalent in the COVID + group: upper respiratory symptoms/head/eyes/ears/nose/throat (HEENT; 37.3% vs 20.9%), constitutional (28.8% vs 19.4%), musculoskeletal (19.5% vs 14.7%), pulmonary (17.6% vs 12.2%), cardiovascular (10.0% vs 7.2%), and gastrointestinal (8.7% vs 8.3%); only 50.2% and 73.3% reported no symptoms at all. Symptoms of post-infectious syndromes were similarly prevalent among the COVID + and COVID - groups at 3 months.
Conclusions: Approximately half of COVID + participants, as compared with one-quarter of COVID - participants, had at least one SARS-CoV-2 symptom at 3 months, highlighting the need for future work to distinguish Long COVID.
Keywords: COVID-19; Long COVID; SARS-CoV-2; coronavirus; outcomes; registry.
. 2022 Dec 27;ciac966.
doi: 10.1093/cid/ciac966. Online ahead of print.
Three-month symptom profiles among symptomatic adults with positive and negative SARS-CoV-2 tests: a prospective cohort study from the INSPIRE group
Erica S Spatz[SUP] 1 [/SUP], Michael Gottlieb[SUP] 2 [/SUP], Lauren E Wisk[SUP] 3 [/SUP], Jill Anderson[SUP] 4 [/SUP], Anna Marie Chang[SUP] 5 [/SUP], Nicole L Gentile[SUP] 6 [/SUP], Mandy J Hill[SUP] 7 [/SUP], Ryan M Huebinger[SUP] 7 [/SUP], Ahamed H Idris[SUP] 8 [/SUP], Jeremiah Kinsman[SUP] 9 [/SUP], Katherine Koo[SUP] 10 [/SUP], Shu-Xia Li[SUP] 11 [/SUP], Samuel McDonald[SUP] 12 [/SUP], Ian D Plumb[SUP] 13 [/SUP], Robert Rodriguez[SUP] 14 [/SUP], Sharon Saydah[SUP] 13 [/SUP], Benjamin Slovis[SUP] 5 [/SUP], Kari A Stephens[SUP] 15 [/SUP], Elizabeth R Unger[SUP] 16 [/SUP], Ralph C Wang[SUP] 14 [/SUP], Huihui Yu[SUP] 11 [/SUP], Bala Hota[SUP] 17 [/SUP], Joann G Elmore[SUP] 3 [/SUP], Robert A Weinstein[SUP] 18 [/SUP], Arjun Venkatesh[SUP] 19 [/SUP]
Affiliations
- PMID: 36573005
- DOI: 10.1093/cid/ciac966
Abstract
Background: Long-term symptoms following SARS-CoV-2 infection are a major concern, yet their prevalence is poorly understood.
Methods: We conducted a prospective cohort study comparing adults with SARS-CoV-2 infection (COVID+) with adults who tested negative (COVID-), enrolled within 28 days of an FDA-approved SARS-CoV2 test result for active symptoms. Sociodemographic characteristics, symptoms of SARS-CoV-2 infection (assessed with the CDC Person Under Investigation Symptom List), and symptoms of post-infectious syndromes (i.e., fatigue, sleep quality, muscle/joint pains, unrefreshing sleep, and dizziness/fainting, assessed with CDC Short Symptom Screener for myalgic encephalomyelitis/chronic fatigue syndrome) were assessed at baseline and 3 months via electronic surveys sent via text or email.
Results: Among the first 1,000 participants, 722 were COVID + and 278 were COVID-. Mean age was 41.5 (SD 15.2); 66.3% were female, 13.4% were Black, and 15.3% were Hispanic. At baseline, SARS-CoV-2 symptoms were more common in the COVID + group than the COVID - group. At 3-months, SARS-CoV-2 symptoms declined in both groups although were more prevalent in the COVID + group: upper respiratory symptoms/head/eyes/ears/nose/throat (HEENT; 37.3% vs 20.9%), constitutional (28.8% vs 19.4%), musculoskeletal (19.5% vs 14.7%), pulmonary (17.6% vs 12.2%), cardiovascular (10.0% vs 7.2%), and gastrointestinal (8.7% vs 8.3%); only 50.2% and 73.3% reported no symptoms at all. Symptoms of post-infectious syndromes were similarly prevalent among the COVID + and COVID - groups at 3 months.
Conclusions: Approximately half of COVID + participants, as compared with one-quarter of COVID - participants, had at least one SARS-CoV-2 symptom at 3 months, highlighting the need for future work to distinguish Long COVID.
Keywords: COVID-19; Long COVID; SARS-CoV-2; coronavirus; outcomes; registry.